category banner


Staphefekt™ represents a breakthrough in the fight against MRSA-bacteria, often referred to as the hospital acquired infection. It is difficult to treat MRSA due to its broad resistance against common antibiotics.

The working mechanism of endolysins is unrelated to that of antibiotics, as a result of which antibiotic resistance is not an issue (antibiotic resistant strains are also killed).

Staphefekt™ is not an antibiotic, but an endolysin. This enzyme is based on phage technology, which enables us - for the first time - to target only unwanted bacteria, leaving the beneficial ones intact.

The first products containing Staphefekt™ are:

  • Staphefekt™ XDR.300 - against S. aureus including MRSA on intact skin
  • Gladskin products for people with skin conditions with an infectious component, such as acne, eczema, rosacea and skin irritation.
XDR.300 (30 ml)
  • Kills Staphylococcus aureus including MRSA
  • To be used on intact skin
  • To be stored at refrigerated conditions (2 – 8°C)
A new approach to treating skin problems with an infectious component:
  • Acne
  • Eczema
  • Rosacea
  • Skin irritation